Universitätsklinikum Essen | Innere Klinik(Tumorforschung) - Westdeutsches Tumorzentrum

Research site

(Unclaimed)

Location

WTZ-Ambulanz, 2. OG. Raum 2.61 Hufelandstr. 55, Essen, North Rhine-Westphalia, Germany

Site insights

Top conditions

Top treatments

Atezolizumab

Bevacizumab

Gemcitabine

Lenalidomide

Platinum

Doxorubicin

Carboplatin

Vemurafenib

Obinutuzumab

Durvalumab

Parent organization

This site is a part of Universitätsklinikum Essen

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

68 of 299 total trials

"InDACtion" vs "3+7" Induction in AML

Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the treatment of elderly AML patients wi...

Active, not recruiting

Acute Myeloid Leukemia (AML)

Drug: standard combination chemotherapy

Drug: decitabine

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma (LYMFOR)

This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic tria...

Enrolling

Marginal Zone Lymphoma

Drug: [68Ga]Ga-PentixaFor

Drug: [18F]Fluorodeoxyglucose

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy (ARDA+)

This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety a...

Active, not recruiting

Multifocal Motor Neuropathy (MMN)

Other: Placebo

Biological: ARGX-117

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) (ENVOL)

This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will...

Enrolling

Duchenne Muscular Dystrophy

Genetic: delandistrogene moxeparvovec

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.Estimate the maximum tolerated dose...

Active, not recruiting

KRAS p.G12C Mutant Advanced Solid Tumors

Drug: Anti PD-1/L1

Drug: sotorasib

A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery (POINTER)

The goal of this clinical trial is to identify the optimal dose of RMC-035 for protection of long-term renal function in adult patients undergoing ca...

Enrolling

Kidney Injury Following Open-Chest Cardiac Surgery

Drug: Placebo

Drug: RMC-035

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

The primary objective of this study is:• To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia...

Invitation-only

Warm Antibody Autoimmune Hemolytic Anemia

Drug: Fostamatinib disodium

A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease (INDIGO)

This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)

Active, not recruiting

IgG4 Related Disease

Drug: Obexelimab

Other: Placebo

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C)

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting

Follicular Lymphoma

Drug: Obinutuzumab

Drug: Copanlisib

Locations recently updated

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting

Diffuse Large B-Cell Lymphoma

Drug: Vincristine Placebo

Drug: Polatuzumab vedotin Placebo

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling

Early Breast Cancer

Drug: Endocrine Therapy of Physician's Choice

Drug: Abemaciclib

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib...

Enrolling

KRAS G12C Lung Cancer

Non-Small Cell Lung Cancer

Drug: Sotorasib

Drug: Divarasib

Locations recently updated

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Drug: Palbociclib

Drug: Giredestrant

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121)

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant co...

Active, not recruiting

Breast Cancer

Drug: Alpelisib

Drug: Inavolisib

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in s...

Active, not recruiting

Sickle Cell Disease

Other: Mitapivat-matching placebo

Drug: Mitapivat

Locations recently updated

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

The primary purpose of this study was to compare the effect of mitapivat versus placebo on hemolytic anemia in participants with alpha- or beta-non-t...

Active, not recruiting

Non-Transfusion-dependent Alpha-Thalassemia

Non-Transfusion-dependent Beta-Thalassemia

Drug: Placebo Matching Mitapivat

Drug: Mitapivat

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (ENERGIZE-T)

The primary purpose of this study is to compare the effect of mitapivat versus placebo on transfusion burden in participants with transfusion-depende...

Active, not recruiting

Transfusion-dependent Alpha-Thalassemia

Transfusion-dependent Beta-Thalassemia

Drug: Placebo Matching Mitapivat

Drug: Mitapivat

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-panBC)

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally...

Enrolling

Metastatic Breast Cancer

Drug: Inavolisib (dose #2)

Drug: Abemaciclib

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a)

This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

Enrolling

Atypical Hemolytic Uremic Syndrome

Drug: Crovalimab

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pha...

Active, not recruiting

Bladder Cancer

Melanoma

Drug: Autogene cevumeran

Drug: Atezolizumab